LEQEMBI is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Eisai Inc.. The primary component is Lecanemab.
| Product ID | 62856-215_aff5d037-645b-4220-95e5-8ac9775f92a0 | 
| NDC | 62856-215 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | LEQEMBI | 
| Generic Name | Lecanemab | 
| Dosage Form | Injection, Solution | 
| Route of Administration | INTRAVENOUS | 
| Marketing Start Date | 2023-01-06 | 
| Marketing Category | BLA / | 
| Application Number | BLA761269 | 
| Labeler Name | Eisai Inc. | 
| Substance Name | LECANEMAB | 
| Active Ingredient Strength | 100 mg/mL | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2024-12-31 | 
| Marketing Start Date | 2023-01-06 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| NDC | Brand Name | Generic Name | 
|---|---|---|
| 62856-212 | LEQEMBI | lecanemab | 
| 62856-215 | LEQEMBI | lecanemab | 
| Mark Image Registration | Serial | Company Trademark Application Date | 
|---|---|
|  LEQEMBI  97151804  not registered Live/Pending | Eisai R&D Management Co., Ltd. 2021-12-01 |